Biolase, INC

BIOLASE, Inc. has been moved to the OTC Pink Market after failing to meet the continued eligibility standards for the OTCQB market.

Biolase, a dental laser company, has filed for Chapter 11 bankruptcy and entered into an asset purchase agreement with Sonendo, a dental technology company, for a potential sale of its assets.

BIOLASE, Inc. has entered into a forbearance agreement with its lenders to avoid immediate loan acceleration and to facilitate a sale of assets through a Chapter 11 bankruptcy filing.

Biolase Inc. received a default notice for missing a payment under its credit agreement, but has been granted an extension until August 30, 2024.

BIOLASE reported its second quarter 2024 financial results, highlighting a 40% gross margin and strong consumable revenue despite overall revenue challenges.

BIOLASE, Inc. issued 3,190,476 shares of common stock in exchange for preferred stock and warrants on July 16, 2024.

BIOLASE, Inc. announces its Q3 2024 financial results while navigating Chapter 11 bankruptcy and an ongoing asset sale process.

BIOLASE's Q2 2024 results reveal a decrease in revenue and a net loss, alongside ongoing concerns about the company's ability to continue as a going concern and its recent delisting from the Nasdaq.

BIOLASE, Inc. reports a slight decrease in revenue for Q1 2024, alongside a net loss and continued efforts to maintain Nasdaq compliance.

BIOLASE, Inc.'s annual 10-K filing details the company's registered securities, voting rights, dividend policies, and corporate governance structure.

BIOLASE, Inc. is holding its annual stockholder meeting on May 2, 2024, seeking approval for director elections, executive compensation, warrant exercises, an incentive plan amendment, auditor ratification, and a potential reverse stock split.

BIOLASE, Inc. is convening its 2024 annual meeting of stockholders to vote on director elections, executive compensation, warrant exercises, a long-term incentive plan amendment, auditor ratification, and a potential reverse stock split.

BIOLASE, Inc. announces a best efforts offering of units and pre-funded units to raise capital for working capital and general corporate purposes.

BIOLASE, Inc. has filed a registration statement for the resale of up to 4,443,760 shares of its common stock, which are issuable upon the exercise of outstanding warrants held by a selling stockholder.

BIOLASE, Inc. plans to offer units and warrants in a best-efforts offering to raise capital for working capital and general corporate purposes.

BIOLASE aims to raise capital by offering units and pre-funded units, each including common stock or warrants and Class A and Class B warrants.

BIOLASE, Inc., a leading provider of advanced laser systems for the dental industry, is offering up to $7.48 million in units and pre-funded units in a best efforts offering.

BIOLASE, Inc. announces a proposed best efforts offering of units and pre-funded units to raise capital for working capital and general corporate purposes.